

10. Wilhelmssen L, Berglund G, Elmfeld D, Fitzsimons T, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. *J Hypertens* 1987; **5**:561-574.
11. American Medical Association. Beta-adrenergic blocking drugs. In *Drug Evaluations Subscription*. Chicago, American Medical Association, I/CV-1:1-12, 1990.
12. Zacharias FJ, Cowen, KJ, Cuthertson PJR, et al. Atenolol in hypertension: a study of long-term therapy. *Postgrad Med J* 1977; **53**(Suppl 3):102-110.
13. Lijnen P, Fagard R, Groeseneken D, et al. The hypertensive effect of captopril in hypertensive patients is age-related. *Methods Find Exp Clin Pharmacol* 1983; **5**:655-660.
14. Tuck ML, Kata LA, Kirkendall WM, et al. Low-dose captopril in mild to moderate geriatric hypertension. *J Am Geriatr Soc* 1986; **34**:693-696.
15. Forette F, Handfield-Jones R, Henry-Amar M, et al. Traitement de l'hypertension arterielle du sujet agé par un inhibiteur de l'enzyme de conversion: l'enalapril. *Presse Med* 1985; **14**:2237-2241.
16. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. *N Engl J Med* 1985; **313**:1617-1620.
17. Valvo E, Bedogna V, Casagrande P, et al. Captopril in patients with Type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. *Am J Med* 1988; **85**:344-348.
18. Parving HH, Hommel E, Nielsen MD, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. *Br Med J* 1989; **299**:533-536.
19. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. *Ann Intern Med* 1990; **112**:707-708.
20. Farrow PR, Wilkinson R. Reversible renal failure during treatment with captopril. *Br Med J* 1979; **1**:1680.
21. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. *N Engl J Med* 1983; **308**:373-376.
22. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1988; **319**:385-392.
23. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. *Br Med J* 1989; **299**:1187-1192.
24. Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting enzyme inhibitor. *Hypertension* 1983; **5**(suppl III):108-113.
25. Wilkins LH, Dustan HP, Walter JF, et al. Enalapril in low-renin essential hypertension. *Clin Pharmacol Ther* 1983; **34**:297-302.
26. Freier PA, Wollam GL, Hall WD, et al. Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension. *Clin Pharmacol Ther* 1984; **36**:731-737.

Corrections

In the article by Avashia JH, Walsh TD, Thomas AJ, Kaye M, and Licata A (*Cleve Clin J Med* 1990; **57**:636-638), reference 2 contained misspellings and should have read as follows:

2. Olsson AM, Jönsson G. Advanced cancer of the prostate combined with hypercalcaemia. *Scand J Urol Nephrol* 1977; **11**:293-296.

In addition, references 3-6 were cited in the text of the article but omitted from the list. The complete entries are provided as follows:

3. George AL Jr, Remler RB, Heim CR, Warner JJ. Hypercalcemia in carcinoma of the prostate: case report and review of the literature. *J Urol* 1987; **137**(2):309-311.
4. Raskin P, McClain CJ, Medsger TA Jr. Hypocalcemia associated with metastatic bone disease. A retrospective study. *Arch Intern Med* 1973; **132**:539-543.
5. Barkin J, Crassweller PO, Roncari DAK, Ondrot J. Hypercalcemia associated with cancer of the prostate without bony metastases. *Urology* 1984; **24**(4):368-371.
6. Benson RC Jr, Riggs BL, Pickard BM, Arnaud CD. Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. *Am J Med* 1974; **56**:821-826.